Clearside Biomedical : January 2021 Corporate Presentation 30.2 MB

Corporate Presentation | January 2021

Forward-Looking Statements

This presenta+on contains forward-looking statements as defined in the Private Securi+es Li+ga+on Reform Act of 1995, as amended. The words "may," "will," "could," "would," "should," "expect," "plan," "an+cipate," "intend," "believe," "es+mate," "predict," "project," "poten+al," "con+nue," "target" and similar expressions are intended to iden+fy forward-looking statements, although not all forward- looking statements contain these iden+fying words. Clearside Biomedical, Inc.'s views as of the date of this presenta+on about future events and are subject to risks, uncertain+es, assump+ons, and changes in circumstances that may cause Clearside's actual results, performance, or achievements to differ significantly from those expressed or implied in any forward-looking statement. Although Clearside believes that the expecta+ons reflected in the forward-looking statements are reasonable, Clearside cannot guarantee future events, results, performance, or achievements. Some of the key factors that could cause actual results to differ from Clearside's expecta+ons include its plans to develop and poten+ally commercialize its product candidates; Clearside's planned clinical trials and preclinical studies for its product candidates; the +ming of and Clearside's ability to obtain and maintain regulatory approvals for its product candidates; the extent of clinical trials poten+ally required for Clearside's product candidates; the clinical u+lity and market acceptance of Clearside's product candidates; Clearside's commercializa+on, marke+ng and manufacturing capabili+es and strategy; Clearside's intellectual property posi+on; and Clearside's ability to iden+fy addi+onal product candidates with significant commercial poten+al that are consistent with its commercial objec+ves. For further informa+on regarding these risks, uncertain+es and other factors you should read the "Risk Factors" sec+on of Clearside's Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on March 13, 2020, Clearside's Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, filed with the SEC on November 10, 2020, and Clearside's other Periodic Reports filed with the SEC. Clearside expressly disclaims any obliga+on to update or revise the informa+on herein, including the forward-looking statements, except as required by law. This presenta+on also contains es+mates and other sta+s+cal data made by independent par+es and by Clearside rela+ng to market size and growth and other data about its industry. This data involves a number of assump+ons and limita+ons, and you are cau+oned not to give undue weight to such es+mates. In addi+on, projec+ons, assump+ons and es+mates of Clearside's future performance and the future performance of the markets in which Clearside operates are necessarily subject to a high degree of uncertainty and risk.

2

2

Developing and Delivering Treatments that Restore and Preserve

Vision for People with Serious Back of the Eye Diseases

Versatile Therapeutic Platform

SCS Microinjector® with proprietary

drug formulations target the

Suprachoroidal Space

Proprietary Access to the Suprachoroidal Space (SCS®)

U?liza?on Across Small Molecules and Gene Therapy

Ability to Target Mul?ple Ocular Diseases

Internal Research & Development Pipeline

External Collaborations for Pipeline Expansion

3

3

Evolution of Injection Procedures to Reach the Back of the Eye

Periocular Injection

Highly variable drug diffusion across the sclera into the eye

Intravitreal Injec-on

Broad diffusion to all areas of the eye including the anterior chamber and lens

Subretinal Injection

Invasive surgery with variable results

Suprachoroidal Space Injection

Novel SCS Microinjector® allows for precise

delivery into the suprachoroidal space

4

4